Morgan Stanley raised the firm’s price target on AstraZeneca (AZN) to $103 from $93 and keeps an Overweight rating on the shares. The firm sees the EU Pharmaceuticals sector set up as neutral into 2026, with fundamentals intact at a low valuation premium compared to history, offset by better EPS growth elsewhere in Europe, the analyst tells investors in a year-ahead outlook note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca: Top Pick in a Growing Pharmaceutical Sector with Promising Pipeline and Resolved Overhangs
- Is AstraZeneca’s Stock (AZN) a Good Investment Right Now?
- Top drug regulator Richard Pazdur preparing to exit FDA, STAT News reports
- AstraZeneca, GSK invited to help shape UK drug pricing regime, Sky News says
- AstraZeneca baxdrostat NDA accepted for priority review by FDA